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Abstract
Subjects and Methods: Seven patients with progressive localized or metastatic chemo-resistant osteosarcoma were treated by
gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest. If no
progression was observed,maintenance by gemcitabine 1000 mg/m2/w for 3 weeks every 28 days was given until failure was
clinically or radiologically evident.
Results. The true objective response rate was 0%.However,disease stabilization and clinical bene® t response were observed
in ® ve patients (70%) for 13± 96 weeks.
Discussion. Postponing the inevitable death with a relatively non-toxic treatment, is, in our opinion, an important issue
especially in young patients.Thus it may be justi® ed and warranted to investigate the activity of gemcitabinein a larger group
of patients with bone sarcomas.
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Introduction
Gemcitabine hydrochloride is a pyrimidine nucle-
oside analog which is applied as a chemotherapeutic
antimetabolite. Gemcitabine inhibits DNA replica-
tion by inhibiting DNA synthesis and by blocking
repair mechanisms through masked chain termina-
tion. Additionally, gemcitabine exerts several other
actions that self-potentiate its cytotoxic activity.
Gemcitabine is usually well tolerated by the patients
and its commonassociated side-effects are notsevere,
and include low grade myelotoxicity, ¯ u-like
syndrome, fever, rash, swelling of the legs, nausea
and vomiting. Gemcitabine has demonstrated
signi® cantclinicalactivity and clinicalbene® t response
in a variety of tumors.
1± 4
Very limited data is available on the use of gemcit-
abine in soft tissue (STS) or bone sarcomas.Gemcit-
abine was found to be active on xenograft of STS
growing in nude mice.
5,6 Palliative effects of gemcit-
abine in a patient with osteosarcoma resistant to
standard chemotherapy
7and experiencewith gemcit-
abine in patients with a variety of progressive
sarcomas
8 have been recently reported by our team.
This report focuses on the effect of gemcitabine on
bone sarcoma.
Treatment protocol
Eligibility criteria were recurrent or metastatic oste-
osarcoma, that either failed to respond to standard
chemotherapy for metastatic or recurrentdisease and
progressed while on chemotherapy, or relapsed after
having been treated with pre-operative or adjuvant
chemotherapy and had demonstrated progressive
disease over a period of 3 months. Standard
chemotherapy for bone sarcoma had to includemeth-
otrexate (MTX),cisplatin (CDDP), adriamycin ADR
and ifosmamide IFX. All the patients had to be 15
years or older,with a Karnofsky’s performance status
(KPS) of at least 40%, and life expectancy of at least
3 months. Any bone sarcoma type was permitted
provided that there was measurable disease,and there
were no central nervous system nor spinal cord
involvement. Signed informed consent was manda-
tory (in case of patients youngerthan 18, parents also
signed).
Baseline evaluation included interview and assess-
ment of symptoms severity and quality of life,
measurement and documentation of marker lesions
by CT scan,ultrasoundor plain X-rays, and complete
blood count and biochemical serum analysis.
Treatment consisted of induction by gemcitabine
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1 week rest. Response to induction course was
assessed by interview (for clinical bene® t response
and quality of life) and by repeated ancillary tests. If
no progressionwas observed,maintenance by gemcit-
abine 1000 mg/m2/w for 3 weeks every 28 days was
given until failure was clinically or radiologically
evident. Evaluation of response, toxicity and quality
of life, was performed every 3 months by interview,
physical examination and ancillary tests,accordingto
the WHO criteria. Progression was determined as
deterioration in clinicalsymptoms,appearance of new
lesions or enlargement of a lesion by at least 25% of
its pre-treatment size. Treatment was to be stopped
in case of life-threatening toxicity, progression of the
disease, or on patient’s refusal to continue.
Patients
Seven patients with primary extremitybone sarcoma,
at age range of 15± 43 years, were enrolled from
December1996 throughAugust1999 into an ongoing
phase II study on gemcitabine in soft tissue or bone
sarcoma.
8All the patients were heavily pre-treated by
various agents according to their disease, such as
adriamycin, ifosfamide, high-dose ifosfamide, meth-
otrexate and etoposide.Theinvolvedsites were mainly
the local tumor bed and lung.The main symptoms
were pain and respiratory problems. Patient
characteristics are detailed inTable 1.
Results
The true objective response rate of osteosarcoma to
gemcitabine was 0%. However, disease stabilization
was observed in 5 out of 7 patients after having failed
on previous treatments. Time to progression varied
from 13 to 96 weeks. It should be noted that disease
stabilization was accompanied by clinical bene® t
response, i.e. improvement of performance status,
alleviation of respiratorysymptoms,alleviation of pain
and reduction in narcotics consumption) and was
observed only in those who also achieved a
progression-free state.
All the patients who failed to respond to gemcit-
abine did not have any clinical bene® t response.The
treatment was well tolerated by the patients. Hema-
tological toxicity was the main concernin ourpatients,
of whom the vast majority was heavily pre-treated.
Other toxic effects included weakness, rash ascites
(with no malignantcellsin repeated taps),limb edema
(deep vein thrombosis was excluded by Doppler-
ultrasound study), and low grade fever.
Discussion
Bone sarcomas carry poor prognosis. Close to one
half of patients succumb to metastatic or locally
advanced disease. Metastatic sarcoma is usually fatal
and treatment options are rather limited. Median
survival from the time metastases are detected is
relatively short, although 20± 25% of patients with
metastatic sarcoma are alive 2 years after diagnosis.
Patients with metastatic sarcoma often are
asymptomatic at the time that a radiograph or CT
reveals metastases,and may remain free of symptoms
for longperiodsof time.Thus,alleviation of symptoms
is not an immediate concern in many patients,
although disease progression is eventually inevitable.
Numerous drug combinations have been assessed
in treated and untreated metastatic disease.The most
effective of these have contained cisplatin, doxoru-
bicin and high-dose methotrexate± leucovorin factor
either as a two- or three-drugregimen;responserates
of the order of 25± 35% have been obtained,although
often based on rather small numbers. The most
important studies on palliative chemotherapy in
metastatic osteosarcoma include cyclophospha-
mide+ doxorubicin+dacarbazine (29 patients,
response rate 24%
9), cisplatin + vincristine+high-
dose methotrexate(29 patients,responserate 28%
10),
dacarbazine+doxorubicin D (20 patients, response
rate 35%
11, Dacarbazine+doxorubicin (19 patients,
response rate 26%
12), and cyclophosphamide+
doxorubicin+actinomycin D (20 patients, response
rate 25%
9). The oncological problem starts after
failure of these agents to affect the disease course.
The patients, especially the younger, may still have
considerable life expectancy and good performance
status, and are eager to be treated, but the caring
oncologist may have nothing to propose.There is a
need for active and minimally toxic agents that can
be given as second line treatment in patients with
STS or bone sarcoma.This was the rationale to use
gemcitabine in this hopeless population of patients
with sarcoma.
The information given to patients before participa-
tion in such study, especially when no more standard
therapy exists for young patient with strong life will,
should give `controlled hope’ but without illusions
for cure.The patients were told that gemcitabine was
highly experimental in osteosarcoma, that there was
no literature on the topic, that the worldwide experi-
ence with the drug was achieved in other diseases,
and that the expected toxicity was relatively mild.
Our results pointed to the important effect of
gemcitabine treatment in heavily pre-treated patients
with progressive bone sarcomas. Gemcitabine was
found to be effective in achieving stabilization of oste-
osarcoma refractory to standard chemotherapy
consisting mainly of adriamycin, high-dose meth-
otrexate, cisplatin and ifosfamide. Although disease
stabilization is generally accepted as failure of
chemotherapy, in this series of cases it should be
regardedas successdueto noteworthy diseasecontrol,
clinical bene® t response and low toxicity pro® le,
especially in view of failure of the accepted drugs.
It is interestingto note that gemcitabine has shown
activity in STS. In a recent study reported by our
8 O.Merimsky et al.T
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Gemcitabine in bone sarcoma 9group
8 we have documented one partial response
(leiomyosarcoma) and one minimal response (angi-
osarcoma),yielding an true objective response rate of
5.5%. An additional six patients achieved stabiliza-
tion of disease, yielding an overall progression-free
rate of 44%. The median time to progression was
more than 27 weeks.
Patel et al.
13 reported their experience in patients
with various types of STS that were given gemcit-
abine in a schedule similar to that in our trial. The
best responses were observed, as in our study, in
patients with angiosarcomaand leiomyosarcoma.The
observations in these trials point to a possible role of
gemcitabine in the treatment in angiosarcoma and
leiomyosarcoma. In our study and in Patel’s study,
gemcitabine monotherapy was given in a schedule of
1 gr/m2/week for 3 weeks every 28 days. A different
schedule is suggested by Spith-Schwalbe et al.:
14
200 mg/m
2 given on days 1,8,15 by 6-h continuous
infusion every 28 days. In their study, 11 heavily
pre-treated patients with STS were enrolled.Theside-
effects were mainly hematological, and the response,
i.e. two partial responses and three cases with disease
stabilizations, were all in pulmonary metastases.
Postponing the inevitable death with a relatively
non-toxic treatment is an important issue especially
in cases of young patients.
It is clear that no treatment recommendations can
be made on the basis of such small series. However,
it may be justi® ed and warranted to investigate the
activity of gemcitabine in a larger group of patients
with bone sarcomas,even as a ® rst line treatment for
recurrent or metastatic disease.
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